GIFLF.US Grifols S.A

Healthcare Pharmaceuticals USA Stocks
20.50 USD
Close of Nov 13, 2026
10.13 12.78
Market cap
USD 8.66B
P/E
15.3x
P/B
1.34x
ROE
9.0%
Dividend yield
0.74%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is GIFLF.US undervalued?

Graham number
Price20.50
Graham value21.46
Discount4.5%

GIFLF.US trades 4.5% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Grifols S.A fundamental analysis

No fundamental analysis for Grifols S.A yet.

Grifols S.A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Grifols S.A

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and mark…

Full company profile